Inovio Pharmaceuticals, Inc. (INO)

Market Cap	105.57M
Revenue (ttm)	9.62M
Net Income (ttm)	-168.43M
Shares Out	268.08M
EPS (ttm)	-0.65
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,743
Open	0.394
Previous Close	0.387
Day's Range	0.375 - 0.394
52-Week Range	0.375 - 2.610
Beta	0.97
Analysts	Hold
Price Target	2.00 (+407.87%)
Earnings Date	Nov 7, 2023

About INO

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medic...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 12, 1998
• Employees: 135
• Stock Exchange: NASDAQ
• Ticker Symbol: INO

Financial Performance

In 2022, INO's revenue was $10.26 million, an increase of 478.23% compared to the previous year's $1.77 million. Losses were -$279.82 million, -7.85% less than in 2021.

Analyst Forecast

According to 3 analysts, the average rating for INO stock is "Hold." The 12-month stock price forecast is $2.0, which is an increase of 407.87% from the latest price.

Price Target

$2.0

(407.87% upside)

Analyst Consensus: Hold